Cargando…

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer

BACKGROUND: Second-line (2 L) chemotherapies for advanced or metastatic gastric cancer have shown improved survival but there is no commonly accepted standard of care. This study examines real-world patient characteristics, treatment patterns, healthcare resource use (HCRU) and clinical outcomes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-Ulloa, David, Amonkar, Mayur, Kothari, Smita, Cheung, Winson Y., Chau, Ian, Zalcberg, John R., Lara Suriñach, Núria, Falcone, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201990/ https://www.ncbi.nlm.nih.gov/pubmed/32370803 http://dx.doi.org/10.1186/s12876-020-01232-z

Ejemplares similares

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Analysis of Costs Associated With Administration of Intravenous Single-Drug Therapies in Metastatic Breast Cancer in a U.S. Population
por: Kruse, Gregory B., et al.
Publicado: (2008)

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2023)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2014)

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
por: Yu, Irene S., et al.
Publicado: (2018)

Selection Bias in Real-World Data Studies Used to Support Health Technology Assessments: A Case Study in Metastatic Cancer
por: Jarada, Tamer N., et al.
Publicado: (2023)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
por: DeBusk, Kendra, et al.
Publicado: (2022)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
por: Matsumoto, Ryuji, et al.
Publicado: (2018)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK
por: Kim, Kun, et al.
Publicado: (2011)

Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective
por: Wills, Allison, et al.
Publicado: (2023)

Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer
por: Shinde, Reshma, et al.
Publicado: (2016)

Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes
por: Lupichuk, Sasha, et al.
Publicado: (2019)

Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada
por: Boyne, Devon J., et al.
Publicado: (2023)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Real-world impact of patient-reported outcome measurement on overall survival, healthcare use and treatment discontinuation in cancer patients
por: Yan, Jessie T, et al.
Publicado: (2023)

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2021)

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
por: Watson, Alexander S., et al.
Publicado: (2022)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
por: Walker, Mark S, et al.
Publicado: (2012)

Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
por: Vera-Llonch, Montserrat, et al.
Publicado: (2011)

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
por: Cheng, Wendy Y., et al.
Publicado: (2021)

Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
por: Giorgi-Pierfranceschi, Matteo, et al.
Publicado: (2015)

A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
por: Karim, Safiya, et al.
Publicado: (2023)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

The Second World War /
por: Churchill, Winston, 1874-1965
Publicado: (1960)

Cannot write session to /tmp/vufind_sessions/sess_se269l69l6r8tppht11up4m4if